Proactive Investors - Run By Investors For Investors

Sareum CEO talks potentially “game changing” CHK1 Phase I trial

Tim Mitchell, chief executive of Sareum Holdings (LON:SAR) tells Proactive that the Checkpoint Kinase 1 (CHK1) clinical trial would transform the business “from a discovery stage company to a clinical stage company.”

The programme, which is being carried out in partnership with the CRT Pioneer Fund, is targeting lung, pancreatic and other cancers and Mitchell says he sees it “as game changing for us.”

The company is awaiting approval to commence two trials, one of which will examine candidate CCT245737 in combination with other chemotherapies, while the other will assess it as a single anti-cancer agents in patients with various cancer types.

Meet Stratex International plc, W Resources PLC, Wishbone Gold PLC, Condor Gold PLC and Kibo Mining PLC at our event, London, 29 June 2017. Register here »
View full SAR profile View Profile

Sareum Holdings Plc Timeline

Big Picture
June 05 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use